Afatinib is recommended as a possible treatment for adults with locally advanced or metastatic non-small-cell lung cancer if:
- their cancer tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and
- they have not had a type of drug called an EGFR-TK inhibitor before.
What does this mean for me?
If you have locally advanced or metastatic non-small-cell lung cancer as described above and your doctor thinks that afatinib is the right treatment, you should be able to have the treatment on the NHS.
Afatinib should be available on the NHS within 3 months of the guidance being issued.
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.